triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 5 of 5

Hammill JA, Afsahi A, Bramson JL, Helsen CW. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes. Methods Mol Biol. 2016;1458:137-57. doi: 10.1007/978-1-4939-3801-8_11. PubMed PMID: 27581020.

Hammill JA, VanSeggelen H, Helsen CW, Denisova GF, Evelegh C, Tantalo DG, Bassett JD, Bramson JL. Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. J Immunother Cancer. 2015 Dec 15;3:55. doi: 10.1186/s40425-015-0099-4. eCollection 2015. PubMed PMID: 26673402; PubMed Central PMCID: PMC4678647.

VanSeggelen H, Tantalo DG, Afsahi A, Hammill JA, Bramson JL. Chimeric antigen receptor-engineered T cells as oncolytic virus carriers. Mol Ther Oncolytics. 2015 Sep 9;2:15014. doi: 10.1038/mto.2015.14. eCollection 2015. PubMed PMID:27119109; PubMed Central PMCID: PMC4782951.

VanSeggelen H, Hammill JA, Dvorkin-Gheva A, Tantalo DG, Kwiecien JM, Denisova GF, Rabinovich B, Wan Y, Bramson JL. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. Mol Ther. 2015 Oct;23(10):1600-10. doi: 10.1038/mt.2015.119. Epub 2015 Jun 30. PubMed PMID: 26122933; PubMed Central PMCID: PMC4817919.